MBRX — Moleculin Biotech Balance Sheet
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro CapNeutral
- $28.91m
- -$21.48m
- 42
- 49
- 41
- 41
Annual balance sheet for Moleculin Biotech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2017 December 31st | 2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 7.71 | 7.13 | 10.7 | 15.2 | 70.9 |
| Net Total Receivables | — | — | 0.011 | 0.164 | 0.496 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 8.3 | 7.97 | 13.5 | 17.2 | 72.5 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.033 | 0.463 | 0.603 | 0.685 | 0.445 |
| Net Intangible Assets | |||||
| Total Assets | 19.5 | 19.6 | 25.2 | 29 | 84.1 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 2.21 | 3.88 | 3.57 | 2.92 | 3.62 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 2.37 | 5.31 | 9.66 | 11.3 | 5.1 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 17.1 | 14.3 | 15.6 | 17.8 | 79 |
| Total Liabilities & Shareholders' Equity | 19.5 | 19.6 | 25.2 | 29 | 84.1 |
| Total Common Shares Outstanding |